Abstract:Background Lung squamous cell carcinoma (LUSC) is prone to metastasis and likely to develop resistance to chemotherapeutic drugs. DNA repair has been reported to be involved in the progression and chemoresistance of LUSC. However, the relationship between LUSC patient prognosis and DNA damage repair genes is still unclear. Methods The clinical information of LUSC patients and tumour gene expression level data were downloaded from the TCGA database. Unsupervised clustering and Cox regression were performed to obtain molecular subtypes and prognosis-related significant genes based on a list including 150 DNA damage repair genes downloaded from the GSEA database. The coefficients determined by the multivariate Cox regression analysis and the expression level of prognosis-related DNA damage repair genes were employed to calculate the risk score, which divided LUSC patients into two groups: the high-risk group and the low-risk group. Immune viability, overall survival, and anticarcinogen sensitivity analyses of the two groups of LUSC patients were performed by Kaplan–Meier analysis with the log rank test, ssGSEA and the pRRophetic package in R software. A time-dependent ROC curve was applied to compare the survival prediction ability of the risk score, which was used to construct a survival prediction model by multivariate Cox regression. The prediction model was used to build a nomogram, the discriminative ability of which was confirmed by C-index assessment, and its calibration was validated by calibration curve analysis. Differentially expressed DNA damage repair genes in LUSC patient tissues were retrieved by the Wilcoxon test and validated by qRT–PCR and IHC. Result LUSC patients were separated into two clusters based on molecular subtypes, of which Cluster 2 was associated with worse overall survival. A prognostic prediction model for LUSC patients was constructed and validated, and a risk score calculated based on the expression levels of ten DNA damage repair genes was employed. The clinical utility was evaluated by drug sensitivity and immune filtration analyses. Thirteen-one genes were upregulated in LUSC patient samples, and we selected the top four genes that were validated by RT–PCR and IHC. Conclusion We established a novel prognostic model based on DNA damage repair gene expression that can be used to predict therapeutic efficacy in LUSC patients.

Integrated expression analysis revealed RUNX2 upregulation in lung squamous cell carcinoma tissues

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

Clinical significance of transcription factor RUNX2 in lung adenocarcinoma and its latent transcriptional regulating mechanism

DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma

Novel mutational landscapes and expression signatures of lung squamous cell carcinoma.

Upregulation Of Hoxa13 As A Potential Tumorigenesis And Progression Promoter Of Lusc Based On Qrt-Pcr And Bioinformatics

Single-cell RNA Sequencing Analysis Revealed Cellular and Molecular Immune Profiles in Lung Squamous Cell Carcinoma

Clinical Roles of the Aberrantly Expressed Lncrnas in Lung Squamous Cell Carcinoma: a Study Based on RNA-sequencing and Microarray Data Mining

Clinicopathological Significance of Ribosomal Protein S6 Kinase A6 in Lung Squamous Cell Carcinoma: an Immunohistochemical and RNA-seq Study.

Pan-cancer landscape of the RUNX protein family reveals their potential as carcinogenic biomarkers and the mechanisms underlying their action

[LINC00668 is Highly Expressed in Lung Squamous Cell Carcinoma and Promotes Tumor Cell Migration and Invasion].

High Expression Levels of CDK1 and CDC20 in Patients With Lung Squamous Cell Carcinoma are Associated With Worse Prognosis

Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and therapeutic response in lung squamous cell carcinoma

Identification of RUNX1T1 as a potential epigenetic modifier in small‐cell lung cancer

Systematic Analysis Using a Bioinformatics Strategy Identifies SFTA1P and LINC00519 As Potential Prognostic Biomarkers for Lung Squamous Cell Carcinoma

Integrated genomic analyses of lung squamous cell carcinoma for identification of a possible competitive endogenous RNA network by means of TCGA datasets.

Identification of tumor-suppressor genes in lung squamous cell carcinoma through integrated bioinformatics analyses

The Expression, Significance And Function Of Cancer Susceptibility Candidate 9 In Lung Squamous Cell Carcinoma: A Bioinformatics And In Vitro Investigation

A novel gene signature related to focal adhesions for distinguishing and predicting the prognosis of lung squamous cell carcinoma

Integrated Analysis of the Functions and Prognostic Values of RNA Binding Proteins in Lung Squamous Cell Carcinoma.